CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

PROFIT WARNING – REDUCTION IN LOSS

This announcement is made by China Biotech Services Holdings Limited (the "**Company**", and together with its subsidiaries, collectively the "**Group**") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on preliminary assessment of the unaudited consolidated management accounts (the "**Management Accounts**") of the Group for the year ended 31 December 2025 ("**FY2025**"), the Group is expected to record a potential net loss of not more than HK$100 million (the "**Loss**"), representing a decrease of approximately 60% as compared to a net loss of HK$252 million for the year ended 31 December 2024.

The significant improvement in the FY2025 was mainly attributable to (i) receiving an insurance claim as compensation income of approximately HK$14.0 million in FY2025 in relation to the damages to construction site in Hainan by a rainstorm happened in the FY2024; (ii) a decrease in research and development costs from the immunotherapy segment; (iii) reduced administrative expenses resulting from successful implementation of costs control measures and (iv) one off impairment loss on property, plant and equipment and intangible assets recorded in FY2024.

As the Company is in the process of preparing the audited consolidated annual results for the FY2025, the information contained in this announcement is only based on a preliminary assessment by the Board with reference to the latest Management Accounts, which have not been finalised as of the date of this announcement. Details of the financial information of the Group will be disclosed in the annual result announcement of the Company, which is expected to be published by the end of March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 6 March 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.